IGHE and asthma: In the PROSPERO study, patients with asthma (IgE levels 1.1–68,628 IU/mL) were treated with omalizumab at a dose of 150 mg every 4 weeks (IgE<30 IU/mL) to 450 mg every 2 weeks (IgE >700 IU/mL) for a median duration of 11.2 months.